DLBCL: cd79-adc + rituximab = 57% ORR
Foll Lym: =70% ORR
Up to 49% discontinuation due to AEs, mostly peripheral neuropathy, but reversible upon trmt cessation.
Adcetris RCHOP for DLBCL
high-risk DLBCL patients, complete response (CR) rate for RCHOP alone was 26%
Adcetris +R-CHOP = 92% ORR, 58% CR
Adcetris for mycoses fungoides: 70%ORR
From Medscape: Adcetris results a likely highlight at ASH
The American Society of Hematology (ASH) 56th Annual Meeting will feature an array of phase 3 clinical trial results, a symposium on the cost of care, a lot of early data on promising experimental agents, and a second round of recommendations from the Choosing Wisely campaign, ASH officials told reporters.
One presentation that is "anxiously awaited," according to ASH President Linda J. Burns, MD, from the University of Minnesota in Minneapolis, provides new clinical trial data on brentuximab vedotin (Adcetris, Seattle Genetics) in Hodgkin's lymphoma.
She spoke at a press briefing held in advance of the meeting, which will run from December 6 to 9 in San Francisco.
Brentuximab is already approved for the treatment of relapsed or refractory Hodgkin's lymphoma.
The new data come from the multinational AETHERA trial, which explores the drug in a different situation — specifically, whether early treatment with brentuximab after autologous stem cell transplantation (ASCT) can prevent progression in patients with Hodgkin's lymphoma who have chemosensitive relapsed/refractory disease and have been identified as being at risk for progression after transplantation (abstract 673).
ASCT has been a standard of care for patients with chemosensitive relapsed/refractory Hodgkin's lymphoma, Dr Burns explained. However, there is a need for novel approaches to improve outcomes after ASCT.
The new brentuximab study represents "one of the highlights" of the meeting, she said.
From Adam Feuerstein's calendar of upcoming biotech events (SGEN listed as one of the most important presenters):
Dec. 6-9: The American Society of Hematology annual meeting. This is the largest medical meeting focused on blood-related cancers like lymphoma and leukemia. As you'd expect, investors pay close attention to what goes on at the ASH annual meeting, as the stocks of biotech and drug companies will move on the clinical data presented there. Which stocks? Here's a partial list of the most important data presenters: Bluebird (BLUE) , Merck (MRK) , Bristol-Myers Squibb (BMY) , Agios Pharma (AGIO) , Epizyme (EPZM) , Acceleron Pharma (XLRN) , Pharmacyclics (PCYC) , Celgene (CELG) and Seattle Genetics (SGEN).
It appears that there are opposing powerful forces pinning the price below $38 and Above $33. It has now lasted ~ 8 months. It acts like if the tutes hedging strategies are highly correlated and using the some bounds.
We need something like a peek at Aethera I to break out higher and impressive results from some of the PII and PI partnerships. An update on LIV I would likely cause a serious melt up.
combination trials are the wave of the future for treatment of cancer . The prices being paid for lesser early clinical drugs makes the valuation of SGEN much higher. SGEN has a majority holder that allows the company to continue with out being aquired. Short term it labels the company as higher risk with fears that if you wait too long for pipeline to develop and do not sell out to big pharma you may miss your boat. Trials are longer drug launches and revenue beats are slow. But other side of the spectrum 2 -3 years you could see SGEN at 70 plus easy. 5 years a 100 price target is plausible. Institutions wont cover on speculatives that far off. If they sold the company of the first offer they recieved share holders would have recieved less than the current PPS . At the time it would have been a large ROI but long term it serves you better to hold this and wait until the partnerships role in
And again. Most bios are down, but SGEN is among the three worst performers in my portfolio today. At least it's consistent.
Ninety-three percent of patients (14/15) achieved a negative PET scan after 2 cycles . All patients with disease bulk were PET-2 negative (10/10). Ninety-two percent of patients achieved a negative PET scan after 4 cycles of therapy.
The study treatment has been well-tolerated. No pulmonary toxicity has been observed. Serious adverse events have been documented in two patients: febrile neutropenia and grade 3 hypertension. One patient discontinued protocol treatment due to the development of grade 3 peripheral neuropathy after one treatment with BV+AVD.
There was really no need for this to give back all of yesterday's gains, but it's unfortunately typical. SGEN continued to fall even at times the NASDAQ was improving.
There is some issue happened yesterday.. we typed the wording correctly... something got messed up. might be some glitch
The Bakers are always working on deals...the one that at some point will involve SGEN will likely be a blockbuster based on their continued accumulation of shares and the large position they have in this stock. They are NOT buying to support the share price but, rather, to make a down payment on a huge payday.
When time is right and the price reflects the value of royalties and pipeline they sure will but we are at least a year away. AETHERA1 should complete next year and it may be enough to get her done.
destined to h#$%$ve much more widespre#$%$d use. There #$%$re #$%$ huge number of #$%$bstr#$%$cts which will be presented #$%$t the Annu#$%$l Meeting of the Americ#$%$n Society of Hem#$%$tology, 12/6-12/9. I #$%$nticip#$%$te #$%$ lot of f#$%$vor#$%$ble publicity